Prostate Cancer

"We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter," says Salim Yazji, MD.

“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective treatment of other bone tumors,” said Daniel Abate-Daga, PhD.

“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.

"Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced, high-risk prostate cancer," says Jiahua Pan, MD.

"The new results show that the 3-step method now used produces fewer insignificant cancer diagnoses than PSA screening,” says Anssi Auvinen, MD, PhD.

Data showed an increase in participant knowledge in 5 of the 10 items on the Prostate Cancer Knowledge Scale and a decrease in all 10 items on the Decisional Conflict Scale after watching the video.

“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.

The authors also project an 85% increase in the number of deaths from prostate cancer per year, which would bring the total number from 375,000 in 2020 to nearly 700,000 by 2040.

"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.

Among the patients who were on treatment for 12 weeks or less, treatment interruptions due to TEAEs occurred in 12.6% of patients, and discontinuations due to TEAEs occurred in 5.3% patients.

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD.

The median radiographic progression-free survival with FG-3246 in mCRPC was 8.7 months.

"We hope that this paper encourages urologists to rethink non definitive treatment/active surveillance for prostate cancer and consider definitive treatment options earlier in the treatment pathway based on evidence that has accumulated," says Mital Patel, MD.

“I would just say that urologists should be focusing much more on the total amount of pattern 4, if they have that information available, than on the ratio of pattern 3 and 4, and therefore the grade group,” says Andrew J. Vickers, PhD.

"The point is healthy, adaptive changes that are sustainable, that you can keep off, because we don't want that rebound/regain," says Jill M. Hamilton-Reeves, PhD, RD, CSO.

“These results are encouraging and suggest that circulating biomarkers may be useful in guiding the use of radium-223 therapy,” says David T. Miyamoto, MD, PhD.

Overall, participating pathologists felt that there is potential to increase diagnostic efficiency by using Galen Prostate in a clinical setting.

"One notable finding was that veterans may not have access to the same quality of prostate cancer care as the US general population," says Olubiyi Aworunse, MD, MPH, PhD.

Treatment with SBRT showed a minimal effect on prostate cancer-specific HRQL measures in regard to urinary incontinence domain scores, urinary irritative/obstructive domain scores, and bowel domain scores.

"Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality,” says Nima Sharifi, MD.

Astellas expects a decision on EU marketing authorization of enzalutamide in nmHSPC by June 2024.

"We suspect that 340B hospitals potentially have some resources or mechanisms that are helping these vulnerable patients maintain adherence,” says Kassem S. Faraj, MD.

Overall, the phase 1/2 trial is designed to explore the safety, tolerability, pharmacokinetics, and preliminary clinical activity of NUV-1511 in patients with advanced solid tumors.

"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

Interest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.

"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.

“The impact of precision medicine in prostate cancer has been significant over a relatively brief period,” says Leonard G. Gomella, MD, FACS.

"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.